GoodCell Raises $17.9 Million to Accelerate Development of Its Actionable Health Technology Platform


WALTHAM, Mass.–()–GoodCell (“LifeVault Bio”), the corporate decoding human well being to lengthen and enhance the standard of life by means of know-how powered by science, right now introduced that it has raised $17.9 million in a most well-liked fairness spherical. GoodCell intends to use this newest funding to help the corporate’s IP for detecting and monitoring amassed genetic variation inside blood cells. Financing will even assist advance the corporate’s big data analytics platform to validate novel functions for its well being monitoring and threat identification options by means of GoodCell Diagnostics and GoodCell’s private biobanking service.

“COVID-19 has demonstrated the importance of solutions that can help people understand their risks and stay ahead of their health,” stated Trevor Perry, Founder and Chief Executive Officer, GoodCell. “We are grateful for a growing investor community that shares our passion for delivering on the promise of personalized healthcare. This latest capital infusion will help us achieve our next stage of development for our platform as we introduce new solutions to the market that change the way individuals, researchers, clinicians and pharmacists predict, identify and monitor disease risk.”

Inherited genetic predisposition to illness has develop into a fixture of analysis and scientific care. However, amassed, or somatic, genetic variations that emerge consequently of age and environmental components stay a comparatively underexplored space of examine. A rising physique of analysis means that amassed genetic variations that culminate within the growth of detrimental variations and trigger harm to DNA inside blood cells – a phenomenon often called clonal hematopoiesis (CH) – could also be linked to larger illness threat. Notably, analysis continues to bolster linkages between these somatic adjustments and the aberrant immune response related to extreme COVID-19 instances. These variations have additionally been correlated to a predisposition towards sure cancers and cardiovascular situations.

GoodCell, which not too long ago filed patent functions for strategies of predicting susceptibility to infectious illness and associated strategies of remedy, uniquely measures and screens each inherited and purchased genetic variations in blood stem cells and different nucleated cells in blood over time. Proceeds from this newest increase will help the continuing buildout of the corporate’s proprietary information aggregation and analytics know-how platform, which goals to decode our cells and harness their insights to advance inhabitants and private well being. The funding can be meant to help exploration and improvement of novel functions for these information streams to help rising science because it relates to pathogen susceptibility, cell high quality, autoimmune and inflammatory illness evaluation and extra.

Notably, the corporate’s newest filings knowledgeable the event of the GoodCell Pathogen Susceptibility Testing Platform and function the inspiration for a not too long ago launched three-stage examine to examine COVID-19 in collaboration with New York Blood Center. The ensuing analysis, anticipated within the coming months, is predicted to present necessary information on COVID-19 threat components that might finally inform the creation of a first-of-its-kind susceptibility check to predict who’s most certainly to develop essentially the most extreme outcomes from the virus.

“Traditional risk factors such as age, weight and chronic conditions are important, but offer an incomplete picture for assessing susceptibility to an ailment,” stated Brad Hamilton, Founder and Chief Science Officer, GoodCell. “Mounting evidence suggests that accumulated genetic variations in our cells play a significant role, as well. Moreover, the ability to evaluate and measure cell quality has the potential to improve quality and consistency of process while potentially reducing costs associated with the manufacturing of cellular products prior to clinical application.”

The funds will even be used to increase GoodCell’s private biobanking service, which is a private well being platform that tracks, screens and helps identification of potential well being threat components and gives long-term storage of cells for potential future therapeutic makes use of, provided by means of a GoodCell membership. The firm intends to apply a portion of this newest spherical of capital to proceed rising its longitudinal precision care providing, broaden its menu of personalised well being screening packages, and scale its gross sales and buyer expertise staff to help new members.

“Our vision is for every person to have greater control over their health by providing access to a platform that helps decode our cells and can extend the quality of life for individuals, their families and all of humankind,” continued Perry. “When science and technology come together, great things happen. We are putting this philosophy into motion with our blood, which we believe contains the building blocks for the medical advances and treatments of tomorrow.”

To be taught extra about GoodCell Diagnostics, go to To be taught extra about GoodCell’s private biobanking service, go to

About GoodCell

GoodCell’s imaginative and prescient is to give each particular person management over their well being by offering entry to a science- backed, technology-forward platform that decodes the frequent language of his or her cells and extends the standard of life for people, their households and all of humankind. The firm’s platform uniquely combines private biobanking, diagnostics and information and is designed to present people and their households the power to securely check, observe and reply to well being dangers, whereas enabling the scientific neighborhood to advance diagnostics and drug improvement at scale to create next-generation safeguards for international well being. Driven by mounting proof in help of mobile remedy and united within the perception that an individual must be empowered to take management of his or her well being, GoodCell is led by a founding staff of science and know-how innovators with a various set of medical analysis. Learn extra at:


Source hyperlink

Write a comment